Physician profile
Pallav Kumar Deka
NPI 1861926636
$1,121.17
in general payments reported to CMS, 2019-2025
22 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $281 · 2023: $189 · 2024: $205 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $130.04 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alnylam Pharmaceuticals INC. | $124.16 | 2024-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $124.09 | 2022-2025 | Verquvo |
| Medtronic, INC. | $107.82 | 2021-2022 | |
| Baxter Healthcare | $92.27 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.28 | 2022-2025 | Lifevest |
| Edwards Lifesciences Corporation | $49.29 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $41.67 | 2024 | |
| Amgen INC. | $38.68 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $38.64 | 2023 | Inpefa |
| Pfizer INC. | $38.61 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.66 | 2022 | |
| Bardy Diagnostics, INC. | $34.05 | 2022 | |
| Scpharmaceuticals INC. | $30.47 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.31 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $27.63 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $27.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.68 | 2023 | |
| Boston Scientific Corporation | $20.31 | 2023 | Watchman Flx |
| Glaxosmithkline, LLC. | $18.04 | 2025 | Shingrix |
| Amarin Pharma, INC. | $16.97 | 2022 | |
| Lundbeck LLC | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pallav Deka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.